Agenus Inc.
NEWS
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and shuttered businesses. Here are five biopharma players staying alive with differentiated candidates against the once promising immuno-oncology target.
As part of a pipeline realignment, Bristol Myers Squibb is returning the rights to Agenus for its proprietary TIGIT bispecific antibody program and terminating their 2021 license, development and commercialization agreement.
Agenus is now looking for alternative pathways to initiate a Phase III trial for BOT/BAL, including potential partnerships.
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
Genentech (Roche) reported Wednesday that its Phase III SKYSCRAPER-01 trial failed to meet its co-primary endpoint of progression-free survival (PFS).
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
Roche announced promising results from the Phase II CITYSCAPE study of tiragolumab plus Tecentriq compared to Tecentriq alone as a treatment for PD-L1-positive metastatic NSCLC.
Lexington, Mass.-based Agenus withdrew its Biologics License Application for balstilimab from the U.S. FDA. The drug is a PD-1 inhibitor or checkpoint inhibitor.
JOBS
IN THE PRESS